Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Person

Johan Luthman

Tracked across 8 events · 51 articles · First seen Apr 13, 2026 · Last active Aug 25, 2026

Sentiment
11
Attention
4
Events
8
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 50
Tech
Impact: Johan Luthman, EVP and Head of Research & Development at Lundbeck, provided commentary on the promising Phase II data for asedebart, highlighting its potential as a novel therapeutic approach.
Jun 14, 2026 · 6 articles
4 0
Tech
Impact: Johan Luthman, EVP and Head of Research & Development at Lundbeck, commented on the progress in neuroscience and Lundbeck's approach to drug development.
Apr 13, 2026 · 6 articles
4 0
Business
Impact: Johan Luthman, EVP and Head of Research and Development at Lundbeck, expressed satisfaction with the orphan drug designation, highlighting the company's commitment to rare diseases.
May 18, 2026 · 7 articles
4 0
Business
Impact: Johan Luthman, EVP and Head of Research and Development at Lundbeck, commented on the significance of the approval for migraine patients in South Korea.
May 26, 2026 · 7 articles
2 0
Regulatory
Impact: Johan Luthman, Lundbeck's EVP R&D, commented on the Fast Track designation as an important milestone for the company's narcolepsy program.
Jul 23, 2026 · 6 articles
4 40
Business
Impact: Retiring after seven years, transition of R&D leadership.
Jul 20, 2026 · 7 articles
2 0
Regulatory
On August 24, 2026, the International — European Commission granted orphan designation to Lundbeck's investigational anti-ACTH monoclonal antibody asedebart (Lu AG13909) for the treatment of Cushing's syndrome of endogenous origin. This designation supports development of…
Impact: Johan Luthman, as Executive Vice President of R&D at Lundbeck, commented on the designation, highlighting its importance and the company's innovation pipeline. His role is primarily communicative in this event.
Aug 24, 2026 · 6 articles
3 0
Business
Impact: Lundbeck's R&D head, announced the milestone and expressed confidence in the program.
Jul 20, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Johan Luthman live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.